Overview

Corneal Crosslinking Treatment Study

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
0
Participant gender:
All
Summary
Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Region Skane
Treatments:
Riboflavin
Criteria
Inclusion Criteria:

- Progress in keratoconic eye. We define progress as an increase in Kmax of 1.0 diopter
in 1 year or 0.5 diopter in 6 months. This increase in Kmax will be accepted as
progression if concomitant changes tomographic parameters.

Exclusion Criteria:

- Concurrent ocular infection or corneal disease other than keratoconus.

- Pregnancy.

- Treatment with Isotretinoin.